Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Non-Current Assets (2020 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Non-Current Assets for 6 consecutive years, with $143.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Assets fell 7.84% year-over-year to $143.2 million, compared with a TTM value of $590.5 million through Dec 2025, down 7.51%, and an annual FY2025 reading of $143.2 million, down 7.84% over the prior year.
  • Non-Current Assets was $143.2 million for Q4 2025 at Xeris Biopharma Holdings, down from $146.2 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $173.0 million in Q2 2023 and bottomed at $6.9 million in Q3 2021.
  • Average Non-Current Assets over 5 years is $149.5 million, with a median of $157.6 million recorded in 2022.
  • The sharpest move saw Non-Current Assets skyrocketed 2231.24% in 2021, then decreased 7.84% in 2025.
  • Year by year, Non-Current Assets stood at $161.8 million in 2021, then dropped by 2.51% to $157.7 million in 2022, then grew by 5.47% to $166.3 million in 2023, then fell by 6.58% to $155.4 million in 2024, then decreased by 7.84% to $143.2 million in 2025.
  • Business Quant data shows Non-Current Assets for XERS at $143.2 million in Q4 2025, $146.2 million in Q3 2025, and $149.1 million in Q2 2025.